AI in Pharmacovigilance 2026: What's Being Deployed, Which Roles Are Changing, and What Skills Now Matter

Three years ago, the discussion around AI and pharmacovigilance was largely theoretical. In 2026, the deployment is real. Pfizer’s global safety operations use machine learning for ICSR prioritisation. Bayer’s PV team published a case study on NLP-assisted case processing. Novartis has integrated AI-driven signal detection into its global safety monitoring programme. The Indian CRO industry, which processes a large share of global ICSR volume, is following the same trajectory.

For pharmacovigilance professionals in India, the question is no longer whether AI will affect the field but how the role is changing, which skills are now required, and which career tracks will be stronger or weaker over the next five years. The picture is more nuanced than either “AI will take all PV jobs” or “nothing will change.”

What AI is actually doing in pharmacovigilance operations today

AI applications in PV have concentrated in three areas: case intake and triage, MedDRA coding assistance, and signal detection. A fourth area, aggregate report generation, is earlier in deployment.

ICSR triage and case processing

The highest-volume, most repetitive task in pharmacovigilance is initial ICSR intake: receiving a case, assessing whether it meets minimum criteria (valid reporter, identifiable patient, suspected product, adverse event), classifying seriousness, assigning priority, and routing it for medical review.

Pfizer deployed a machine learning-based triage system across its global safety database that classifies incoming ICSRs by seriousness and priority before a human reviewer touches the case. The system reduces the time a human medical reviewer spends on case intake by approximately 40%, based on figures Pfizer shared in its 2023 industry publication. Reviewers handle the cases the model has already triaged; their time goes into evaluation rather than intake.

Oracle’s Argus Safety platform, used across the majority of large pharma safety databases globally, now includes AI-assisted features for case processing. These include automated population of structured data fields from narrative text and suggested MedDRA coding terms based on adverse event descriptions. CROs running global caseloads through Argus are beginning to use these features, though adoption rates vary.

Bayer’s pharmacovigilance operations have used NLP-based systems to extract adverse event data from unstructured sources, including social media and patient forums, at a scale that would be operationally impossible with manual review. Bayer has been public about this through conference presentations at DIA and ISPE meetings.

MedDRA coding assistance

MedDRA coding, the translation of an adverse event description into a standardised term in the Medical Dictionary for Regulatory Activities hierarchy, has historically required trained human coders applying their judgement to ambiguous language. AI coding assistants now suggest the most appropriate MedDRA Preferred Term given the input language, with confidence scores and alternative term suggestions.

Tools from Saama Technologies, Cognizant Life Sciences, and the AI layers within Veeva Vault Safety are widely used at Indian CROs processing global caseloads for US and EU clients. The human coder’s role shifts from performing the initial code selection to reviewing and approving or correcting the AI’s suggestion.

The error profile of AI coding assistants is specific and learnable. They perform reliably on common adverse events with standard terminology, and less reliably on unusual presentations, multi-system events, or adverse events described in non-standard clinical language. A PV professional who understands where the AI makes systematic errors can catch those errors efficiently; one who treats AI output as essentially correct will miss a predictable class of mistakes.

Signal detection

Signal detection, identifying unexpected patterns in safety data that might indicate a new or changed risk, has always been constrained by the volume of data a human analyst can feasibly review. IQVIA’s Vigilance Detect platform uses statistical algorithms and ML models to identify disproportionality signals across large safety databases, including the FDA’s FAERS, WHO’s VigiBase, and sponsor proprietary databases.

Novartis has integrated AI-assisted signal detection into its safety monitoring programme, using it to prioritise signals for human review rather than relying solely on traditional disproportionality analysis. This does not reduce the need for trained signal detection analysts; it changes what they spend their time doing, from running statistical queries to evaluating the clinical significance of AI-surfaced signals.

At Indian CROs, signal detection work is concentrated in specialist teams. The AI tools are largely running at the sponsor level, with CRO teams involved in data preparation and preliminary analysis. But as CROs grow their signal detection capabilities for smaller clients, the same pattern will appear domestically.

Aggregate report generation

PSURs, PBRERs, and RMPs require structured clinical writing, regulatory knowledge, and medical judgement. AI-assisted drafting tools are now producing first-draft sections for routine periodic safety reports, with human safety writers reviewing and editing.

This is the area where AI application is most recent and where quality concerns are highest. The consequences of an error in a PSUR section submitted to EMA or USFDA are significant, and regulatory agencies have begun asking questions about AI involvement in submitted documents. The human safety writer role is not at risk, but the expectation of AI literacy in drafting workflows is growing.

How junior PV roles are actually changing

The entry-level pharmacovigilance role of 2022, one focused primarily on case intake, data entry, and routine MedDRA coding, is being restructured. The tasks most amenable to automation are precisely those that junior associates spent the most time on.

The change is not that junior roles are disappearing. Global ICSR volumes are growing, driven by post-marketing surveillance obligations, digital adverse event reporting channels, and expanded pharmacovigilance requirements in markets like India, China, and Brazil. More cases exist to be processed.

The change is that the human value-add at junior level is shifting from execution to verification. A junior PV associate in 2026 at a CRO using AI-assisted tools spends less time entering structured data and selecting MedDRA terms from scratch, and more time reviewing AI-generated outputs for accuracy, completeness, and compliance with regulatory definitions. The skills required are different: critical assessment of AI outputs, understanding of systematic AI failure modes, and enough regulatory knowledge to catch errors that the system makes with apparent confidence.

Junior associates who treat this verification task casually, approving AI outputs without genuinely reviewing them, are both creating compliance risk for their employers and failing to develop the clinical judgement that separates senior PV professionals from junior ones.

What new skills matter most

AI output validation

The foundational new skill for PV professionals at every level is the ability to critically assess AI-generated outputs. For ICSR processing, this means:

• Knowing the regulatory definitions of seriousness, expectedness, and causality well enough to catch errors in AI classification
• Understanding MedDRA hierarchy (SOC, HLGT, HLT, PT, LLT) well enough to identify when an AI-suggested term is technically plausible but clinically inaccurate
• Recognising narrative extraction errors, where an AI has pulled the wrong adverse event from a complex case narrative

This is fundamentally a domain knowledge task, not a technology task. The professionals best positioned to validate AI outputs are those with the strongest grounding in PV fundamentals.

Platform familiarity with AI-integrated safety systems

Oracle Argus Safety, Veeva Vault Safety, IQVIA Vigilance, and Saama’s SMART Signals platform all have AI-assisted features that are now standard at global CROs. Knowing how these features work, not just how to navigate the case screen but how the AI assistance is integrated and where its outputs appear in the workflow, is a practical requirement for CRO employment.

Signal evaluation and clinical reasoning

As AI tools surface more candidate signals for review, the bottleneck shifts to clinical evaluation. A signal detection analyst needs to assess whether a statistical signal represents a real clinical risk, a confounded observation, or a data artefact. This requires pharmacology knowledge, epidemiological reasoning, and familiarity with the therapeutic area. These are skills that cannot be automated.

Regulatory writing with AI-assisted tools

For PV professionals moving into aggregate report writing, understanding how to use AI drafting tools effectively, how to prompt them usefully, how to edit their outputs efficiently, and how to identify the specific categories of error they produce in regulatory writing contexts, is now a practical skill.

Which PV career tracks are at risk and which are growing

PV role	AI impact	Outlook
Junior ICSR Associate (data entry, coding)	High — task profile changing significantly	Stable volume, restructured role
Senior Case Processor / Medical Reviewer	Moderate — AI handles intake, human handles evaluation	Stable, growing demand
Signal Detection Analyst	Moderate — AI surfaces signals, humans evaluate	Growing, especially for specialists
Aggregate Report Specialist (PSUR/PBRER)	Low-moderate — AI assists drafting	Stable to growing
PV Quality Auditor	Low — AI creates audit demand	Growing
PV System Administrator	Low — AI integration creates system roles	Growing
Drug Safety Physician / Medical Officer	Very low — regulatory and medical judgement	Growing, shortage in India
PV Regulatory Affairs (RMP, variation)	Low	Stable

The roles with the weakest outlook are those where the core task is literal data entry and routine code selection with no clinical judgement component. These existed at scale at Indian CROs that process high volumes of routine cases; those specific task profiles will shrink.

The roles that are growing require either clinical/medical knowledge (Drug Safety Physician, Senior Medical Reviewer, Signal Detection Analyst) or technology system expertise (PV System Administrator, AI output quality auditor). The middle of the career ladder, Senior PV Associate through PV Manager level, remains robust because this is where clinical judgement and regulatory knowledge intersect.

What Pune’s CRO ecosystem is doing

Pune’s pharmacovigilance operations are concentrated at Syngene’s global safety centre, Lambda Therapeutic Research’s PV division, Veeda Clinical Research, Sciformix (part of Labcorp), and the PV units of pharma companies including Cipla, Lupin, Wockhardt, and Glenmark.

Syngene has integrated AI-assisted case processing for its major global accounts, using tools within Oracle Argus Safety’s AI feature set and a custom NLP layer for unstructured case data. Lambda and Veeda are in pilot phases with automated triage tools.

The domestic pharma companies (Cipla, Lupin, Glenmark, Wockhardt) are at an earlier stage of AI integration in their PV operations, primarily because their India-centric case volumes have a different profile than the high-volume global caseloads that most benefit from AI triage. Adoption will accelerate as AI tools become standard in Argus and Veeva Vault Safety configurations.

The practical implication for Pune-based PV job seekers: familiarity with Oracle Argus Safety (including its AI-assisted features), Veeda Vault Safety, and MedDRA coding assistants will differentiate candidates at CRO interviews. Employers running global caseloads are already using these tools and prefer candidates who understand them.

The training consequence

The pharmacovigilance training curriculum that adequately prepared a junior PV associate in 2022 does not fully prepare one for 2026. The additional requirements are:

1. Hands-on exposure to AI-assisted case processing workflows, even if only in training simulations
2. A thorough grounding in MedDRA fundamentals deep enough to validate AI term selections rather than just apply them
3. Understanding of seriousness, expectedness, and causality criteria precise enough to catch AI classification errors
4. Basic familiarity with how LLMs process clinical text, specifically the failure modes relevant to adverse event narratives

iLearn CRI’s Pharmacovigilance programme incorporates AI-integrated workflow training alongside the foundational ICH E2 series, MedDRA, and Argus Safety coverage that has always been core to the curriculum. The goal is not to train PV professionals to build AI systems, but to train them to work effectively and critically alongside the AI tools that are already standard in Pune’s CRO operations.

The analogy to draw is from clinical data management 10 years ago, when CDM professionals had to adapt from paper CRFs to EDC platforms. The ones who adapted fast became more valuable; the ones who resisted found themselves working on smaller and smaller legacy projects. AI in pharmacovigilance is that same transition, and it is already underway.

For a deeper look at how the CRA and PV career tracks compare in terms of trajectory, skills, and temperament fit, see our comparison of pharmacovigilance and CRA careers. For current salary benchmarks across both tracks, the CRA salary breakdown for India 2026 covers the numbers in detail.